Gene Therapy Reaches XLRS Milestone - Summary - MDSpire

Gene Therapy Reaches XLRS Milestone

  • May 25, 2026

Share

Objective:

To evaluate the safety and efficacy of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), in a clinical trial.

Key Findings:
  • Structural and functional improvements were observed in treated adults.
  • Foveal schisis closure was confirmed in four of six treated adults in Cohort 4.
  • No serious adverse events were reported across all cohorts.
Interpretation:

Limitations:
  • The study included a small sample size of nine adults and three pediatric patients.
  • Control patients may receive treatment after one year of observation, which could affect outcomes.
Conclusion:

Original Source(s)

Gene Therapy Reaches XLRS Milestone

  • May 25, 2026

Related Content

"All Eyes on DME"

Genentech launches diabetic macular edema awareness campaign fronted by actor and comedian, Damon Wayans

  • May 22, 2026

  • 3 min
A Topical Route to Neuroprotection?

Topical peptide therapy targets excitotoxicity in retinal degeneration

  • May 22, 2026

  • 3 min
Screen Time Linked to Higher Myopia Odds

Meta-analysis found odds rose most sharply between 1 and 4 hours of daily digital screen exposure before increasing more gradually thereafter